Loading...
BELLUS Health Inc.
BLU.TO•TSX
Healthcare
Biotechnology
CA$19.48
CA$-0.02(-0.10%)

Financial performance has remained strong, with revenue growing from $4000.00 in Q2 2022 to $3000.00 in Q1 2023. Gross profit continued to perform well, with margins at 100% in the latest quarter. Operating income reached -$27.72M in Q1 2023, holding a steady -924133% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$25.008M. Net income dropped to -$25.06M, keeping EPS at -$0.20. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan